Peter Valent

72.1k total citations · 8 hit papers
900 papers, 40.5k citations indexed

About

Peter Valent is a scholar working on Immunology, Hematology and Genetics. According to data from OpenAlex, Peter Valent has authored 900 papers receiving a total of 40.5k indexed citations (citations by other indexed papers that have themselves been cited), including 431 papers in Immunology, 329 papers in Hematology and 228 papers in Genetics. Recurrent topics in Peter Valent's work include Mast cells and histamine (390 papers), Food Allergy and Anaphylaxis Research (176 papers) and Acute Myeloid Leukemia Research (168 papers). Peter Valent is often cited by papers focused on Mast cells and histamine (390 papers), Food Allergy and Anaphylaxis Research (176 papers) and Acute Myeloid Leukemia Research (168 papers). Peter Valent collaborates with scholars based in Austria, Germany and United States. Peter Valent's co-authors include Wolfgang R. Sperr, Rudolf Valenta, Cem Akin, Klaus Lechner, Hans‐Peter Horny, Christian Sillaber, Peter Bettelheim, Karl Sotlar, Dietrich Kraft and Dean D. Metcalfe and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Peter Valent

874 papers receiving 39.6k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia

2011 1.4k citations Johannes Zuber, Harald Herrmann et al. profile →
Diagnostic criteria and classification of mastocytosis: a consensus proposal

2001 738 citations Peter Valent, Cem Akin et al. profile →
New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients

2007 540 citations Michael Pfeilstöcker, Thomas Nösslinger et al. Blood profile →
Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets

2007 532 citations Peter Valent, Giulio Superti‐Furga et al. Blood profile →
Identification of Profilin as a Novel Pollen Allergen; IgE Autoreactivity in Sensitized Individuals

1991 526 citations Rudolf Valenta, Christian Sillaber et al. profile →
Profilins constitute a novel family of functional plant pan-allergens.

1992 515 citations Rudolf Valenta, Peter Valent et al. profile →
Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes

2012 457 citations Peter Valent, Hans‐Peter Horny et al. Journal of Allergy and Clinical Immunology profile →
Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts

2016 394 citations Peter Valent, Cem Akin et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter Valent Austria	97	16.7k	12.0k	9.7k	9.6k	8.6k	900	40.5k
K. Frank Austen United States	118	20.1k 1.2×	8.3k 0.7×	9.6k 1.0×	3.7k 0.4×	5.4k 0.6×	540	40.8k
Peter E. Lipsky United States	107	23.2k 1.4×	2.7k 0.2×	8.4k 0.9×	4.6k 0.5×	13.8k 1.6×	661	46.7k
Juliet N. Barker United States	85	17.3k 1.0×	2.1k 0.2×	4.4k 0.5×	8.4k 0.9×	2.8k 0.3×	559	31.3k
Raif S. Geha United States	99	19.4k 1.2×	6.5k 0.5×	5.3k 0.5×	2.4k 0.3×	1.8k 0.2×	501	31.8k
Yoshiya Tanaka Japan	80	9.6k 0.6×	2.4k 0.2×	5.7k 0.6×	5.2k 0.5×	14.5k 1.7×	1.1k	30.4k
John J. O’Shea United States	110	31.2k 1.9×	1.6k 0.1×	11.2k 1.2×	3.5k 0.4×	5.1k 0.6×	323	49.8k
James G. Krueger United States	126	30.7k 1.8×	7.9k 0.7×	6.8k 0.7×	2.3k 0.2×	5.7k 0.7×	495	49.7k
Lawrence B. Schwartz United States	83	11.5k 0.7×	6.9k 0.6×	5.0k 0.5×	789 0.1×	4.1k 0.5×	263	22.2k
Jordan S. Pober United States	97	15.7k 0.9×	6.3k 0.5×	12.0k 1.2×	3.0k 0.3×	1.4k 0.2×	362	37.0k
Gary S. Firestein United States	88	10.2k 0.6×	2.0k 0.2×	12.1k 1.2×	3.3k 0.3×	11.4k 1.3×	308	33.7k

Countries citing papers authored by Peter Valent

Since Specialization

Citations

This map shows the geographic impact of Peter Valent's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Valent with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Valent more than expected).

Fields of papers citing papers by Peter Valent

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Valent. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Valent. The network helps show where Peter Valent may publish in the future.

Co-authorship network of co-authors of Peter Valent

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Valent. A scholar is included among the top collaborators of Peter Valent based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Valent. Peter Valent is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Klampfl, Thorsten, Eszter Doma, Omar Torres‐Quesada, et al.. (2025). CDK6 kinase inhibition unmasks metabolic dependencies in BCR::ABL1+ leukemia. Cell Death and Disease. 16(1). 107–107. 2 indexed citations

Eder, Thomas, Pablo Fernández‐Pernas, Johannes Schmoellerl, et al.. (2025). Transcriptional and epigenetic rewiring by the NUP98::KDM5A fusion oncoprotein directly activates CDK12. Nature Communications. 16(1). 4656–4656. 1 indexed citations

Sadovnik, Irina, Barbara Peter, Gabriele Stefanzl, et al.. (2024). Coronavirus Receptor Expression Profiles in Human Mast Cells, Basophils, and Eosinophils. Cells. 13(2). 173–173. 5 indexed citations

Onida, Francesco, Nico Gagelmann, Yves Chalandon, et al.. (2024). Management of adult patients with CMML undergoing allo-HCT: recommendations from the EBMT PH&G Committee. Blood. 143(22). 2227–2244. 8 indexed citations

Naumann, Nicole, Johannes Lübke, William Shomali, et al.. (2021). Clinical and histopathological features of myeloid neoplasms with concurrent Janus kinase 2 (JAK2) V617F and KIT proto‐oncogene, receptor tyrosine kinase (KIT) D816V mutations. British Journal of Haematology. 194(2). 344–354. 9 indexed citations

Heibl, Sonja, Bettina Gisslinger, Peter Bettelheim, et al.. (2020). Clinical, Hematologic, Biologic and Molecular Characteristics of Patients with Myeloproliferative Neoplasms and a Chronic Myelomonocytic Leukemia-Like Phenotype. Cancers. 12(7). 1891–1891. 4 indexed citations

Salama, Mohamed E., Karin Hartmann, Gregor Eisenwort, et al.. (2018). Variability of PD-L1 expression in mastocytosis. Blood Advances. 2(3). 189–199. 7 indexed citations

Boehm, Thomas, Birgit Reiter, Robin Ristl, et al.. (2018). Massive release of the histamine‐degrading enzyme diamine oxidase during severe anaphylaxis in mastocytosis patients. Allergy. 74(3). 583–593. 41 indexed citations

Greiner, Georg, Franz Ratzinger, Nadine Witzeneder, et al.. (2017). Digital Droplet PCR: Next Generation KIT D816V Testing As Advanced Tool for Diagnosis and Prognostication in Mastocytosis. Blood. 130. 2927–2927. 1 indexed citations

10.

Mancini, Manuela, Cristina Papayannidis, Michela Rondoni, et al.. (2017). Polo-like Kinase-1 and Aurora Kinase A As Novel Therapeutic Targets in Neoplastic Mast Cells. Blood. 130. 5290–5290. 1 indexed citations

11.

Valent, Peter, Cem Akin, & Dean D. Metcalfe. (2016). Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. Blood. 129(11). 1420–1427. 394 indexed citations breakdown →

12.

Arock, Michel, Cem Akin, Olivier Hermine, & Peter Valent. (2015). Current treatment options in patients with mastocytosis: status in 2015 and future perspectives. European Journal Of Haematology. 94(6). 474–490. 43 indexed citations

13.

Blatt, Katharina, Harald Herrmann, Gregor Hoermann, et al.. (2014). Identification of Campath-1 (CD52) as Novel Drug Target in Neoplastic Stem Cells in 5q-Patients with MDS and AML. Clinical Cancer Research. 20(13). 3589–3602. 23 indexed citations

14.

Sakaguchi, Shinya, Alexandra Schebesta, Nicole Boucheron, et al.. (2013). The Transcription Factor MAZR Preferentially Acts as a Transcriptional Repressor in Mast Cells and Plays a Minor Role in the Regulation of Effector Functions in Response to FcεRI Stimulation. PLoS ONE. 8(10). e77677–e77677. 8 indexed citations

15.

Einwallner, Elisa, Gerlinde Mitterbauer‐Hohendanner, Martin Bilban, et al.. (2013). Endogenous Erythroid Colony Formation in Chronic Myeloid Leukemia: A Recurrent Finding Associated with Persistent Minimal Residual Disease Under Imatinib. Stem Cells and Development. 22(23). 3043–3051. 1 indexed citations

16.

Gleixner, Karoline V., Barbara Peter, Alexander Gruze, et al.. (2010). Polo-like Kinase 1 (Plk1) as a Novel Drug Target in Chronic Myeloid Leukemia: Overriding Imatinib Resistance with the Plk1 Inhibitor BI 2536. Cancer Research. 70(4). 1513–1523. 74 indexed citations

17.

Niedoszytko, Marek, Bogusław Nedoszytko, Magdalena Lange, et al.. (2008). Vascular Endothelial Growth Factor (VEGF) promoter gene polymorphism in mastocytosis. A study of the European Competence Network on Mastocytosis (ECNM). Data Archiving and Networked Services (DANS). 1 indexed citations

18.

Flicker, Sabine, Peter Steinberger, Tanja Ball, et al.. (2006). Spatial clustering of the IgE epitopes on the major timothy grass pollen allergen Phl p 1: Importance for allergenic activity. Journal of Allergy and Clinical Immunology. 117(6). 1336–1343. 48 indexed citations

19.

Swoboda, Ines, Nicole A. de Weerd, Prem L. Bhalla, et al.. (2002). Mutants of the major ryegrass pollen allergen, Lol p 5, with reduced IgE-binding capacity: candidates for grass pollen-specific immunotherapy. European Journal of Immunology. 32(1). 270–280. 63 indexed citations

20.

Bankl, Hans, et al.. (1999). Mast cells are augmented in deep vein thrombosis and express a profibrinolytic phenotype. Human Pathology. 30(2). 188–194. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact